Cargando…

Characteristics of Dapagliflozin Responders: A Longitudinal, Prospective, Nationwide Dapagliflozin Surveillance Study in Korea

INTRODUCTION: Sodium glucose co-transporter 2 (SGLT2) inhibitors, such as dapagliflozin, have demonstrated favorable effects in patients with type 2 diabetes (T2D). However, there are limited reports in the literature regarding the glucose-lowering effects of SGLT2 inhibitors in actual clinical sett...

Descripción completa

Detalles Bibliográficos
Autores principales:	Han, Eugene, Kim, Ari, Lee, Sung Jae, Kim, Je-Yon, Kim, Jae Hyeon, Lee, Woo Je, Lee, Byung-Wan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6064582/ https://www.ncbi.nlm.nih.gov/pubmed/29998370 http://dx.doi.org/10.1007/s13300-018-0470-9

Ejemplares similares

A Comparison of the Pharmacokinetics and Safety of Dapagliflozin Formate, an Ester Prodrug of Dapagliflozin, to Dapagliflozin Propanediol Monohydrate in Healthy Subjects
por: Kim, Hyun Chul, et al.
Publicado: (2023)

Blood glucose levels and bodyweight change after dapagliflozin administration
por: Kim, Hyunah, et al.
Publicado: (2021)

Effect of the Sodium-Glucose Cotransporter 2 Inhibitor, Dapagliflozin, on Genitourinary Infection in an Animal Model of Type 2 Diabetes
por: Choi, Jin Bong, et al.
Publicado: (2020)

Use of dapagliflozin in patients with advanced diabetic kidney disease
por: Park, Hyun Sun, et al.
Publicado: (2018)

Efficacy of Gemigliptin Add-on to Dapagliflozin and Metformin in Type 2 Diabetes Patients: A Randomized, Double-Blind, Placebo-Controlled Study (SOLUTION)
por: Lee, Byung Wan, et al.
Publicado: (2023)

Not so critical appraisal of dapagliflozin
por: Doggrell, Sheila A
Publicado: (2014)

Dapagliflozin attenuates diabetes-induced diastolic dysfunction and cardiac fibrosis by regulating SGK1 signaling
por: Lee, Seul-Gee, et al.
Publicado: (2022)

Fournier Gangrene in a Patient With Type 2 Diabetes Mellitus Treated With Dapagliflozin: A Case Report
por: Moon, Jae Young, et al.
Publicado: (2021)

Comparative cardiovascular outcomes in type 2 diabetes patients taking dapagliflozin versus empagliflozin: a nationwide population-based cohort study
por: Lim, Jaehyun, et al.
Publicado: (2023)

Dapagliflozin: BMS 512148; BMS-512148
Publicado: (2012)

An exploration of the experience of dapagliflozin in clinical practice
por: Anitha, Anuba Paulvarnan, et al.
Publicado: (2022)

A Nonlinear Mixed Effects Pharmacokinetic Model for Dapagliflozin and Dapagliflozin 3-O-glucuronide in Renal or Hepatic Impairment
por: van der Walt, J-S, et al.
Publicado: (2013)

Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add‐on to metformin in patients with type 2 diabetes
por: Müller‐Wieland, Dirk, et al.
Publicado: (2018)

Pharmacokinetic and pharmacodynamic drug–drug interactions between evogliptin and empagliflozin or dapagliflozin in healthy male volunteers
por: Kim, Dasohm, et al.
Publicado: (2023)

Association of Parkinson’s disease with ischemic stroke in Korea: A nationwide longitudinal cohort study in Korea
por: Kim, Woo Yup, et al.
Publicado: (2021)

Dapagliflozin-Induced Acute-on-Chronic Liver Injury
por: Levine, Joshua A., et al.
Publicado: (2016)

Dapagliflozin: A Review in Type 2 Diabetes
por: Dhillon, Sohita
Publicado: (2019)

Dapagliflozin: A Review in Type 1 Diabetes
por: Paik, Julia, et al.
Publicado: (2019)

The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58
por: Mosenzon, Ofri, et al.
Publicado: (2021)

Dapagliflozin in patients with COVID-19: truth or dare
por: Rossello, Xavier, et al.
Publicado: (2021)

Dapagliflozin in patients with COVID-19: mind the kidneys
por: Reis, Thiago, et al.
Publicado: (2022)

Current Status of Dapagliflozin in Congestive Heart Failure
por: Palandurkar, Gopal, et al.
Publicado: (2022)

Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF)
por: Serenelli, Matteo, et al.
Publicado: (2020)

Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
por: List, James F., et al.
Publicado: (2009)

Mental-Physical Comorbidity in Korean Adults: Results from a Nationwide General Population Survey in Korea
por: Kim, Ji-Hyun, et al.
Publicado: (2016)

Dapagliflozin induces apoptosis by downregulating cFILP(L) and increasing cFILP(S) instability in Caki-1 cells
por: Jang, Ji Hoon, et al.
Publicado: (2022)

Risk of Cardiovascular Events and Medical Cost of Dapagliflozin and Dipeptidyl Peptidase-4 Inhibitors
por: Seong, Jong-Mi, et al.
Publicado: (2021)

Longitudinal impact of dapagliflozin treatment on ventricular repolarization heterogeneity in patients with type 2 diabetes
por: Sato, Tatsuya, et al.
Publicado: (2019)

Retrospective Analysis of the Efficacy of Dapagliflozin in Patients with Type 2 Diabetes in a Primary Clinic in Korea
por: Park, Sang Hyun, et al.
Publicado: (2019)

Fournier’s gangrene with dapagliflozin in a rural hospital: a case report
por: Elbeddini, Ali, et al.
Publicado: (2021)

Association between ischemic stroke and seropositive rheumatoid arthritis in Korea: A nationwide longitudinal cohort study
por: Lee, Dong Hyun, et al.
Publicado: (2021)

Dapagliflozin, SGLT2 Inhibitor, Attenuates Renal Ischemia-Reperfusion Injury
por: Chang, Yoon-Kyung, et al.
Publicado: (2016)

Pharmacokinetics of a Fixed-Dose Combination Product of Dapagliflozin and Linagliptin and Its Comparison with Co-Administration of Individual Tablets in Healthy Humans
por: Park, Jin-Woo, et al.
Publicado: (2022)

Combined antidiabetic benefits of exenatide and dapagliflozin in diabetic mice
por: Tatarkiewicz, K, et al.
Publicado: (2014)

The effect of dapagliflozin treatment on epicardial adipose tissue volume
por: Sato, Takao, et al.
Publicado: (2018)

Dapagliflozin-induced Late-onset Euglycemic Diabetic Ketoacidosis
por: Iqbal, Iqra, et al.
Publicado: (2019)

Correction to: Dapagliflozin: A Review in Type 1 Diabetes
por: Paik, Julia, et al.
Publicado: (2019)

Correction to: Dapagliflozin: A Review in Type 2 Diabetes
por: Dhillon, Sohita
Publicado: (2019)

Dapagliflozin Does Not Modulate Atherosclerosis in Mice with Insulin Resistance
por: Taberner-Cortés, Alida, et al.
Publicado: (2020)

Effect of Dapagliflozin on the Functioning of Rat Liver Mitochondria In Vitro
por: Belosludtseva, N. V., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4mhnk8inkk24lie6qfefbs1221